• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.质子泵抑制剂和组胺-2 受体拮抗剂的使用与两种基于人群的研究中的胃癌风险。
Br J Cancer. 2020 Jul;123(2):307-315. doi: 10.1038/s41416-020-0860-4. Epub 2020 May 5.
2
Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.质子泵抑制剂和组胺 2 受体拮抗剂的使用与两项基于人群的研究中的肝癌风险。
Aliment Pharmacol Ther. 2018 Jul;48(1):55-64. doi: 10.1111/apt.14796. Epub 2018 May 9.
3
Use of proton pump inhibitors and risk of pancreatic cancer.质子泵抑制剂的使用与胰腺癌风险。
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):926-930. doi: 10.1002/pds.4576. Epub 2018 Jun 20.
4
Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.质子泵抑制剂与组胺 2 受体拮抗剂治疗期间艰难梭菌感染风险的比较:使用通用数据模型的 15 年医院队列研究。
J Gastroenterol Hepatol. 2020 Aug;35(8):1325-1330. doi: 10.1111/jgh.14983. Epub 2020 Jan 29.
5
Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction.在台湾,长期使用质子泵抑制剂或组胺-2受体拮抗剂是否为缺铁性贫血的危险因素?一种被忽视的临床药物相互作用。
Fam Pract. 2025 Feb 7;42(2). doi: 10.1093/fampra/cmad090.
6
Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.质子泵抑制剂与组胺 2 受体拮抗剂用于胃癌风险:基于人群的队列研究。
Am J Gastroenterol. 2021 Jun 1;116(6):1211-1219. doi: 10.14309/ajg.0000000000001167.
7
Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.质子泵抑制剂和组胺 2 受体拮抗剂的使用与缺铁。
Gastroenterology. 2017 Mar;152(4):821-829.e1. doi: 10.1053/j.gastro.2016.11.023. Epub 2016 Nov 24.
8
Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study.质子泵抑制剂与流感、肺炎和 COVID-19 易感性的关联:来自大型基于人群队列研究的证据。
Elife. 2024 Jul 16;13:RP94973. doi: 10.7554/eLife.94973.
9
Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.质子泵抑制剂与胃癌风险:一项基于人群的队列研究。
Br J Cancer. 2009 May 5;100(9):1503-7. doi: 10.1038/sj.bjc.6605024. Epub 2009 Apr 7.
10
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.质子泵抑制剂维持治疗与胃癌风险:瑞典一项基于全国人口的队列研究
BMJ Open. 2017 Oct 30;7(10):e017739. doi: 10.1136/bmjopen-2017-017739.

引用本文的文献

1
A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer.质子泵抑制剂对胃癌风险影响的荟萃分析。
Medicine (Baltimore). 2025 Jul 11;104(28):e43053. doi: 10.1097/MD.0000000000043053.
2
Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective.质子泵抑制剂与胃癌风险:一项系统综述、证据综合及生命历程流行病学视角分析
BMJ Open Gastroenterol. 2025 Apr 19;12(1):e001719. doi: 10.1136/bmjgast-2024-001719.
3
Predictors for the Development of Hypergastrinemia in Maintenance Treatment for Mild Gastroesophageal Reflux Disease Using a Half-dose Proton Pump Inhibitor.使用半量质子泵抑制剂维持治疗轻度胃食管反流病时高胃泌素血症发生的预测因素
J Neurogastroenterol Motil. 2025 Jan 31;31(1):119-128. doi: 10.5056/jnm24128.
4
Potential Risks Associated With Long-term Use of Proton Pump Inhibitors and the Maintenance Treatment Modality for Patients With Mild Gastroesophageal Reflux Disease.长期使用质子泵抑制剂与轻度胃食管反流病患者维持治疗方式相关的潜在风险
J Neurogastroenterol Motil. 2024 Oct 30;30(4):407-420. doi: 10.5056/jnm24059.
5
Proton pump inhibitors and risk of gastrointestinal cancer: A meta‑analysis of cohort studies.质子泵抑制剂与胃肠道癌症风险:队列研究的荟萃分析
Oncol Lett. 2023 Nov 20;27(1):28. doi: 10.3892/ol.2023.14161. eCollection 2024 Jan.
6
Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies.长期使用质子泵抑制剂的患者患胃癌的风险:观察性和干预性研究的系统评价和荟萃分析。
Dig Dis Sci. 2023 Sep;68(9):3732-3744. doi: 10.1007/s10620-023-08018-9. Epub 2023 Jul 11.
7
PPIs and gastric cancer: any causal relationship?PPIs 与胃癌:存在因果关系吗?
Acta Biomed. 2023 Jun 14;94(3):e2023096. doi: 10.23750/abm.v94i3.14105.
8
Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.质子泵抑制剂与胃癌和结直肠癌风险的关联:一项系统评价和荟萃分析。
Front Pharmacol. 2023 Mar 16;14:1129948. doi: 10.3389/fphar.2023.1129948. eCollection 2023.
9
Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses.常用药物暴露与胃癌风险:一项Meta分析的伞形综述
Cancers (Basel). 2023 Jan 6;15(2):372. doi: 10.3390/cancers15020372.
10
Use of proton pump inhibitors for the risk of gastric cancer.质子泵抑制剂用于胃癌风险。
Medicine (Baltimore). 2022 Dec 9;101(49):e32228. doi: 10.1097/MD.0000000000032228.

本文引用的文献

1
Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.质子泵抑制剂使用时间与胃癌和食管癌风险。
Cancer Epidemiol. 2019 Oct;62:101585. doi: 10.1016/j.canep.2019.101585. Epub 2019 Aug 21.
2
Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth.长期质子泵抑制剂治疗的安全性与并发症:更接近真相
Gastroenterology. 2019 Sep;157(3):604-607. doi: 10.1053/j.gastro.2019.07.039. Epub 2019 Jul 30.
3
Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis.质子泵抑制剂长期使用与胃癌风险的关系:系统分析。
J Gastroenterol Hepatol. 2019 Nov;34(11):1898-1905. doi: 10.1111/jgh.14759. Epub 2019 Jul 24.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.埃索美拉唑和阿司匹林在 Barrett 食管(AspECT)中的应用:一项随机析因试验。
Lancet. 2018 Aug 4;392(10145):400-408. doi: 10.1016/S0140-6736(18)31388-6. Epub 2018 Jul 26.
6
Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for : a retrospective cohort analysis.长期使用质子泵抑制剂是治疗后患胃癌的一个风险因素:一项回顾性队列分析。
Gut. 2018 Oct;67(10):1908-1910. doi: 10.1136/gutjnl-2017-315710. Epub 2017 Dec 22.
7
Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.药物-癌症关联性的药物流行病学研究的考虑因素。
Basic Clin Pharmacol Toxicol. 2018 May;122(5):451-459. doi: 10.1111/bcpt.12946. Epub 2018 Jan 15.
8
Adverse Events of Proton Pump Inhibitors: Potential Mechanisms.质子泵抑制剂的不良事件:潜在机制
Curr Drug Metab. 2018;19(2):142-154. doi: 10.2174/1389200219666171207125351.
9
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for : a population-based study.长期质子泵抑制剂治疗后胃癌发展的风险:一项基于人群的研究。
Gut. 2018 Jan;67(1):28-35. doi: 10.1136/gutjnl-2017-314605. Epub 2017 Oct 31.
10
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.质子泵抑制剂维持治疗与胃癌风险:瑞典一项基于全国人口的队列研究
BMJ Open. 2017 Oct 30;7(10):e017739. doi: 10.1136/bmjopen-2017-017739.

质子泵抑制剂和组胺-2 受体拮抗剂的使用与两种基于人群的研究中的胃癌风险。

Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.

机构信息

Centre for Public Health, Queen's University Belfast, Belfast, UK.

Belfast Health and Social Care Trust, Belfast, UK.

出版信息

Br J Cancer. 2020 Jul;123(2):307-315. doi: 10.1038/s41416-020-0860-4. Epub 2020 May 5.

DOI:10.1038/s41416-020-0860-4
PMID:32367073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7374738/
Abstract

BACKGROUND

Studies have shown increased gastric cancer risk in users of proton pump inhibitors (PPI) and histamine-2 receptor antagonists, questioning the safety of gastric acid suppression. Therefore, we conducted a case-control study within the Scottish Primary Care Clinical Informatics Unit (PCCIU) database and a cohort study in the UK Biobank.

METHODS

In PCCIU, five controls were matched to cases diagnosed in 1999-2011, and medications were determined from GP records. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression. In the UK Biobank, medications were self-reported at cohort entry 2006-2010, and gastric cancer ascertained from cancer registries until 2014. Hazard ratios (HR) were calculated using Cox regression.

RESULTS

PCCIU contained 1119 cases and 5394 controls. UK Biobank contained 250 cases in 471,779 participants. PPI users had a higher gastric cancer risk in PCCIU and UK Biobank when applying a 1-year lag (adjusted OR = 1.49, 95% CI 1.24, 1.80; adjusted HR = 1.28, 95% CI 0.86, 1.90, respectively), but these associations were attenuated when using a 2-year lag (adjusted OR = 1.13, 95% CI 0.91, 1.40; adjusted HR = 1.15, 95% CI 0.73, 1.82, respectively).

CONCLUSIONS

Overall, we observed little consistent evidence of an increased risk of gastric cancer with PPI use.

摘要

背景

研究表明,质子泵抑制剂(PPI)和组胺 2 受体拮抗剂的使用者胃癌风险增加,这对胃酸抑制的安全性提出了质疑。因此,我们在苏格兰初级保健临床信息学单位(PCCIU)数据库中进行了病例对照研究,并在英国生物库中进行了队列研究。

方法

在 PCCIU 中,将五个对照与 1999-2011 年诊断的病例相匹配,并从全科医生记录中确定药物。使用条件逻辑回归计算比值比(OR)和 95%置信区间(CI)。在英国生物库中,药物在 2006-2010 年入组时自我报告,通过癌症登记处确定胃癌直到 2014 年。使用 Cox 回归计算危险比(HR)。

结果

PCCIU 包含 1119 例病例和 5394 例对照。英国生物库包含 471779 名参与者中的 250 例病例。在 PCCIU 和英国生物库中,应用 1 年滞后时,PPI 用户的胃癌风险较高(调整后的 OR=1.49,95%CI 1.24,1.80;调整后的 HR=1.28,95%CI 0.86,1.90),但当使用 2 年滞后时,这些关联减弱(调整后的 OR=1.13,95%CI 0.91,1.40;调整后的 HR=1.15,95%CI 0.73,1.82)。

结论

总体而言,我们观察到 PPI 使用与胃癌风险增加的证据很少一致。